Article Text

Download PDFPDF
Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy
  1. Andreas Jenke1,
  2. Eva-Maria Ruf1,
  3. Thomas Hoppe2,
  4. Michael Heldmann1,
  5. Stefan Wirth1
  1. 1Department of Neonatology, HELIOS Children's Hospital, Wuppertal, Witten/Herdecke University, Germany
  2. 2Laboratoriumsmedizin Köln, Dres. Wisplinghoff, Cologne, Germany
  1. Correspondence to Andreas CW Jenke, Children's Hospital, Helios Klinikum Wuppertal,42283, Wuppertal, Germany; andreas.jenke{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Studies on probiotics for prevention of necrotising enterocolitis (NEC) show a risk reduction across all studies from 6.6% (165/2493) in the untreated to 2.5% (62/2433) in the treated patients.1 However, modest limitations in all studies, for example, uncharacteristically high-baseline rate of NEC2- warrant cautious risk–benefit consideration. This ambivalence is reflected by the current European Society of Paediatric Gastroenterology, Hepatology and Nutrition guidelines,3 not officially recommending their use whereas a recent cochrane review4 suggests a change in practice.

Monochorial-diamnial monocygotic twin pregnancy was diagnosed …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.